



FOR IMMEDIATE RELEASE

OPMEDIC GROUP RELEASES *ANDROTEST*[™] A NEW ANDROPAUSE SCREENING PANEL AIMED TO IMPROVE MEN'S HEALTH IN THEIR AGING YEARS

Montreal, QC, June 16, 2009 – OPMEDIC GROUP INC. (“OPMEDIC GROUP”) (TSX: “OMG”), a healthcare-related services company in fertility, laboratories and surgeries providing services and facilities to patients and surgeons through a network of private clinics in the province of Québec, is pleased to announce that it has developed through its division PROCREA Cliniques a new test panel called *Androtest*[™]. The *Androtest*[™] offers a complete screening profile as an aid to the diagnosis and the management of andropause, an age-related condition that affects men over 45 years of age due to a decline in testosterone levels (late onset hypogonadism or andropause).

The *Androtest*[™] includes an extended panel of biochemical markers and a sophisticated follow-up report that will help the physician with the patient's medical history diagnose andropause.

Besides the decrease in sex drive that is often the main reason for a medical consultation by men, recent studies show that the hormonal unbalance caused by andropause increases a man's risk of coronary artery disease, depression, lack of energy and mental acuity in addition to a decrease in bone mass and an increase in abdominal fat.

The symptoms that may be associated with andropause may include one or more of the following :

- Hot flashes and excessive sweating without physical activity
- Loss of muscle and bone mass and strength
- Lack of energy with diminished physical activity
- Joint and muscle pain
- Abdominal obesity
- Sadness, irritability, and overall lack of interest
- Depression
- Sleep problems
- Decline in mental acuity, concentration and short term memory
- Loss of sex drive, leading to a decrease in performance and sexual activities

“The aging man has been neglected both in research and public health interventions which have almost exclusively focused on the treatment of chronic diseases. The addition of *Androtest*[™] to our line of laboratory services further confirms the objective of PROCREA Cliniques to offer our patients and

physicians the most advanced clinical services in the area of men's health.”, commented Dr. Pierre St-Michel, CEO and president of OPMEDIC GROUP.

About OPMEDIC GROUP

OPMEDIC GROUP is a company incorporated under the laws of the Province of Québec which provides healthcare-related services including surgical and endoscopic facilities and services to patients and surgeons (with its OPMEDIC division), fertility treatments, medical imaging, laboratory services and diagnostic procedures (with its PROCREA Cliniques division) and sperm banking services (with its PROCREA Cryopreservation Centre subsidiary). OPMEDIC GROUP's Common Shares trade on the Toronto Stock Exchange under the symbol “OMG”.

This news release does not constitute an offer to sell or to solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offering would be unlawful. This news release contains certain forward-looking statements that reflect the current views and/or expectations of OPMEDIC GROUP with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

Not for distribution to United States newswire services or for dissemination in the United States.

The Content of this press release has not been approved by nor submitted to the TSX which assumes no liability therefore.

SOURCE AND INFORMATION:

Paulo BOUÇA
Vice President Business Development and
Chief Operating Officer
(514) 345-8535, x 2254
pbouca@opmedicgroup.com